Human cytomegalovirus neutralising antibodies and increased risk of coronary artery disease in Indian population

Heart

Volumn 98, Issue 13, 2012, Pages 982-987

  Mundkur, Lakshmi Ashutosh ^a   Shivanandan, Hemapriys ^a   Hebbagudi, Sridhara ^a   Endrész, Valeria ^b   Varma, Meenakshi ^a   Rao, Veena ^a   Gonczol, Eva ^c   Kakkar, Vijay Vir ^a,d  

^a THROMBOSIS RESEARCH INSTITUTE   (India)

^b UNIVERSITY OF SZEGED   (Hungary)

^c NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

^d THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; IMMUNOGLOBULIN G; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; PHOSPHOLIPASE A2;

ADULT; ANALYSIS OF VARIANCE; ANTIBODY TITER; ARTICLE; ASIAN; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INDIAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; VIRUS NEUTRALIZATION;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INDIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84862017263     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-301850     Document Type: Article

References (30)

1. Margulies BJ, Browne H, Gibson W. Identification of the human cytomegalovirus G protein-coupled receptor homologue encoded by UL33 in infected cells and enveloped virus particles. Virology 1996;225:111-25. (Pubitemid 26390057)
2. Penfold ME, Dairaghi DJ, Duke GM, et al. Cytomegalovirus encodes a potent alpha chemokine. Proc Natl Acad Sci U S A 1999;96:9839-44. (Pubitemid 29398819)
3. Saederup N, Aguirre SA, Sparer TE, et al. Murine cytomegalovirus CC chemokine homolog MCK-2 (m131-129) is a determinant of dissemination that increases inflammation at initial sites of infection. J Virol 2001;75:9966-76. (Pubitemid 32900131)
4. Hsich E, Zhou YF, Paigen B, et al. Cytomegalovirus infection increases development of atherosclerosis in Apolipoprotein-E knockout mice. Atherosclerosis 2001;156:23-8. (Pubitemid 32429591)
5. Adler B, Sinzger C. Endothelial cells in human cytomegalovirus infection: one host cell out of many or a crucial target for virus spread? Thromb Haemost 2009;102:1057-63.
6. Marshall GS, Ricciardi RP, Rando RF, et al. An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies. J Infect Dis 1990;162:1177-81. (Pubitemid 20353602)
7. Eggers M, Radsak K, Enders G, et al. Use of recombinant glycoprotein antigens gB and gH for diagnosis of primary human cytomegalovirus infection during pregnancy. J Med Virol 2001;63:135-42. (Pubitemid 32142270)
8. Eggers M, Bader U, Enders G. Combination of microneutralization and avidity assays: improved diagnosis of recent primary human cytomegalovirus infection in single serum sample of second trimester pregnancy. J Med Virol 2000;60:324-30. (Pubitemid 30054287)
9. Eryol NK, Kilic H, Gul A, et al. Are the high levels of cytomegalovirus antibodies a determinant in the development of coronary artery disease? Int Heart J 2005;46:205-9.
10. Haider AW, Wilson PW, Larson MG, et al. The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study. J Am Coll Cardiol 2002;40:1408-13. (Pubitemid 35192864)
11. Adler SP, Hur JK, Wang JB, et al. Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis 1998;177:209-12. (Pubitemid 28030454)
12. Danesh J, Wong Y, Ward M, et al. Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population based study of coronary heart disease. Heart 1999;81:245-7. (Pubitemid 29116332)
13. Shanker J, Maitra A, Rao VS, et al. Rationale, design & preliminary findings of the Indian atherosclerosis Research study. Indian Heart J 2011;62:286-95.
14. Gonczol E, Furlini G, Ianacone J, et al. A rapid microneutralization assay for cytomegalovirus. J Virol Methods 1986;14:37-41. (Pubitemid 16029426)
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
16. Alexander T, Mehta S, Mullasari A, et al. Systems of care for ST-elevation myocardial infarction in India. Heart 2012;98:15-17.
17. Wood A, Pell J, Patel A, et al. Prevention of cardiovascular disease in a rural region of India and strategies to address the unmet need. Heart 2011;97:1373-8.
18. Enas EA, Singh V, Munjal YP, et al. Reducing the burden of coronary artery disease in India: challenges and opportunities. Indian Heart J 2008;60:161-75.
19. Zaidi AK, Awasthi S, deSilva HJ. Burden of infectious diseases in South Asia. BMJ 2004;328:811-15. (Pubitemid 38446380)
20. Kaur A, Kassis N, Hale CL, et al. Direct relationship between suppression of virus-specific immunity and emergence of cytomegalovirus disease in simian AIDS. J Virol 2003;77:5749-58. (Pubitemid 36538968)
21. Epstein SE, Zhu J, Najafi AH, et al. Insights into the role of infection in atherogenesis and in plaque rupture. Circulation 2009;119:3133-41.
22. Bason C, Corrocher R, Lunardi C, et al. Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis. Lancet 2003;362:1971-7. (Pubitemid 37548421)
23. Rott D, Zhu J, Zhou YF, et al. IL-6 is produced by splenocytes derived from CMV-infected mice in response to CMV antigens, and induces MCP-1 production by endothelial cells: a new mechanistic paradigm for infection-induced atherogenesis. Atherosclerosis 2003;170:223-8. (Pubitemid 37377793)
24. Menschikowski M, Rosner-Schiering A, Eckey R, et al. Expression of secretory group IIA phospholipase A(2) in relation to the presence of microbial agents, macrophage infiltrates, and transcripts of proinflammatory cytokines in human aortic tissues. Arterioscler Thromb Vasc Biol 2000;20:751-62. (Pubitemid 30151691)
25. Mallat Z, Steg PG, Benessiano J, et al. Circulating Secretory Phospholipase A2 Activity Predicts Recurrent Events in Patients With Severe Acute Coronary Syndromes. J Am Coll Cardiol 2005;46:1249-57. (Pubitemid 41615545)
26. Jaross W, Eckey R, Menschikowski M. Biological effects of secretory phospholipase A(2) group IIA on lipoproteins and in atherogenesis. Eur J Clin Invest 2002;32:383-93. (Pubitemid 36223427)
27. Niessen HW, Krijnen PA, Visser CA, et al. Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? Cardiovasc Res 2003;60:68-77. (Pubitemid 38373477)
28. Zhu J, Quyyumi AA, Norman JE, et al. Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels. J Am Coll Cardiol 1999;34:1738-43.
29. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-8. (Pubitemid 40075677)
30. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-16. (Pubitemid 351679597)